Company intelligence / Profile preview

Sonavex

Baltimore, Maryland, United Statessonavex.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Initial clinical studies demonstrated that users without ultrasound experience could accurately assess AV fistula maturation using the EchoSure system. The company has received FDA Investigational Device Exemption approval to conduct a pivotal randomized controlled trial ("MAFASA") to further validate its technology. Data were presented at major medical conferences and support the utility of their platform in dialysis clinics.

Therapeutic areas: CardiovascularNephrology
Modalities: DeviceBiologicArtificial intelligence-enabled device
Industry: Medical Imaging

Partnerships

Not specifically disclosed as of June 2025. Investors include several institutional venture funds with expertise in medtech/vascular/dialysis sectors.

Beyond the preview

Go deeper on Sonavex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sonavex.

Explore the full profile